for Journals by Title or ISSN
for Articles by Keywords
help
Journal Cover Nature Reviews Drug Discovery
  [SJR: 11.742]   [H-I: 235]   [324 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
   Published by NPG Homepage  [135 journals]
  • Emptying the stores: lysosomal diseases and therapeutic strategies
    • Emptying the stores: lysosomal diseases and therapeutic strategies

      Emptying the stores: lysosomal diseases and therapeutic strategies, Published online: 17 November 2017; doi:10.1038/nrd.2017.214

      NatureArticleSnippet(type=short-summary, markup=

      Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed.

      , isJats=true)Emptying the stores: lysosomal diseases and therapeutic strategies, Published online: 2017-11-17; doi:10.1038/nrd.2017.2142017-11-17
      DOI: 10.1038/nrd.2017.214
       
  • Metabolic disease: Ectopic olfactory receptor activation reverses obesity
    • Metabolic disease: Ectopic olfactory receptor activation reverses obesity

      Metabolic disease: Ectopic olfactory receptor activation reverses obesity, Published online: 17 November 2017; doi:10.1038/nrd.2017.230

      Metabolic disease: Ectopic olfactory receptor activation reverses obesity, Published online: 2017-11-17; doi:10.1038/nrd.2017.2302017-11-17
      DOI: 10.1038/nrd.2017.230
       
  • Eric Rubin
    • Eric Rubin

      Eric Rubin, Published online: 17 November 2017; doi:10.1038/nrd.2017.228

      NatureArticleSnippet(type=short-summary, markup=

      Eric Rubin, vice president of clinical oncology at Merck & Co, discusses tumour-agnostic approvals, immunotherapy combinations and the modernization of clinical trial eligibility criteria.

      , isJats=true)Eric Rubin, Published online: 2017-11-17; doi:10.1038/nrd.2017.2282017-11-17
      DOI: 10.1038/nrd.2017.228
       
  • Sepsis: Stalking a new target
    • Sepsis: Stalking a new target

      Sepsis: Stalking a new target, Published online: 17 November 2017; doi:10.1038/nrd.2017.238

      Sepsis: Stalking a new target, Published online: 2017-11-17; doi:10.1038/nrd.2017.2382017-11-17
      DOI: 10.1038/nrd.2017.238
       
  • Cancer: Bispecific antibody directs T cells to solid tumours
    • Cancer: Bispecific antibody directs T cells to solid tumours

      Cancer: Bispecific antibody directs T cells to solid tumours, Published online: 17 November 2017; doi:10.1038/nrd.2017.237

      Cancer: Bispecific antibody directs T cells to solid tumours, Published online: 2017-11-17; doi:10.1038/nrd.2017.2372017-11-17
      DOI: 10.1038/nrd.2017.237
       
  • The atopic dermatitis market
    • The atopic dermatitis market

      The atopic dermatitis market, Published online: 06 November 2017; doi:10.1038/nrd.2017.192

      NatureArticleSnippet(type=short-summary, markup=

      The market for atopic dermatitis therapies is dominated by topical corticosteroids, but is poised to change with the recent approvals of dupilumab and crisaborole, as well as other drugs in clinical development.

      , isJats=true)The atopic dermatitis market, Published online: 2017-11-06; doi:10.1038/nrd.2017.1922017-11-06
      DOI: 10.1038/nrd.2017.192
       
  • JAK inhibition as a therapeutic strategy for immune and inflammatory
           diseases
    • JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

      JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Published online: 06 November 2017; doi:10.1038/nrd.2017.201

      NatureArticleSnippet(type=short-summary, markup=

      Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines. Jakinibs — small-molecule inhibitors of JAKs — have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies. This Review discusses the biology, development and efficacy of jakinibs in the treatment of immune and inflammatory diseases.

      , isJats=true)JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Published online: 2017-11-06; doi:10.1038/nrd.2017.2012017-11-06
      DOI: 10.1038/nrd.2017.201
       
  • Respiratory diseases: Gq protein inhibition induces airway relaxation
    • Respiratory diseases: Gq protein inhibition induces airway relaxation

      Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.203

      Nature Reviews Drug Discovery, Published online: 30 October 2017; doi:10.1038/nrd.2017.2032017-10-30
      DOI: 10.1038/nrd.2017.203
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.80.146.251
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016